SCHEDULE OF PARTIES TO THE FORM OF AMENDED EMPLOYMENT AGREEMENT
EXHIBIT 10.3
SCHEDULE OF PARTIES TO THE FORM OF
AMENDED EMPLOYMENT AGREEMENT
Each of the parties identified in the table below is party to an employment agreement with Advanced Medical Optics, Inc. (the “Company”) substantially in the form attached to the Company’s Form 10 as Exhibit 10.9(a). Each party’s employment agreement is identical except for such party’s base salary, position, agreement date and prior agreements, each of which is set forth in the table below. The agreements of Messrs. Xxxxx and Trenary were previously amended in October 2004 for the purpose of reflecting their then titles and adjusted salaries, and Xx. Xxxxxxx’x employment agreement was further amended in November 2007, filed as Exhibit 10.5(d) to the Company’s Form 10-K for the year ended December 31, 2007. All of the employment agreements were further amended on July 31, 2008 substantially in the form attached as Exhibit 10.2 to the Company’s Form 10-Q for the quarter ended June 27, 2008.
| EMPLOYEE NAME |
BASE SALARY |
POSITION |
AGREEMENT DATE |
PRIOR AGREEMENTS | |||||
| Xxxxxxx X. Xxxxx |
$ | 520,000 | President and Chief Operating Officer | April 8, 2002, amended October 1, 2004 | Agreement between Allergan and Executive dated April 8, 2002 | ||||
| Xxxxxxx X. Xxxx |
$ | 380,000 | Executive Vice President and President, Corneal Refractive Group | December 14, 2004 (but effective only upon completion of the VISX merger) | Not applicable | ||||
| Xxxx X. Xxxx |
$ | 342,400 | Executive Vice President, Strategy and Corporate Development | April 8, 2002 | Agreement between Allergan and Executive dated April 8, 2002 | ||||
| X. Xxxxxxx Xxxxxxx III |
$ | 380,000 | Executive Vice President, Global Public Policy and Medical Education | April 24, 2002, amended October 1, 2004 and November 15, 2007 | Agreement between Allergan and Executive dated April 24, 2002 | ||||
| Xxxxx X. Xxxxxxx |
$ | 321,000 | Executive Vice President, Administration, and Secretary | January 18, 2002 | Retention Agreement among the Company, Allergan and the Executive dated January 18, 2002 | ||||
